Search research articles
Contact Us
Filters
Showing results (11-20 of 31) with videos related to
Page
of 4
Sort By:
BJU International
|
April 25, 2017
Men's Eating and Living (MEAL) study (CALGB 70807 [Alliance]): recruitment feasibility and baseline demographics of a randomized trial of diet in men on active surveillance for prostate cancer
J Kellogg Parsons, John P Pierce, James Mohler, et al.
Contemporary Clinical Trials Communications
|
July 17, 2018
PALINA: A phase II safety study of palbociclib in combination with letrozole or fulvestrant in African American women with hormone receptor positive HER2 negative advanced breast cancer
Filipa Lynce, Mervat Saleh, Ayesha Shajahan-Haq, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
February 6, 2017
Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study-CALGB 30607 (Alliance)
Maria Q Baggstrom, Mark A Socinski, Xiaofei F Wang, et al.
Breast Cancer Research and Treatment
|
February 10, 2025
A randomized phase II trial of nab-paclitaxel with or without mifepristone for advanced triple-negative breast cancer
Nan Chen, Margarite Matossian, Poornima Saha, et al.
The Oncologist
|
August 11, 2019
Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial
Daniel J George, Colin Hessel, Susan Halabi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 16, 2017
Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial
Toni K Choueiri, Susan Halabi, Ben L Sanford, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 2, 2018
Corrigendum to 'Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update' [Eur J Cancer 94 (May 2018) 115-125]
Toni K Choueiri, Colin Hessel, Susan Halabi, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 19, 2018
Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update
Toni K Choueiri, Colin Hessel, Susan Halabi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 4, 2016
Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance)
Maura N Dickler, William T Barry, Constance T Cirrincione, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 23, 2020
Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer
Aranzazu Fernandez-Martinez, Ian E Krop, David W Hillman, et al.
Page
of 4
Search research articles
Search
Showing results (11-20 of 31) with videos related to
Sort By:
Page
of 4
BJU International
|
April 25, 2017
Men's Eating and Living (MEAL) study (CALGB 70807 [Alliance]): recruitment feasibility and baseline demographics of a randomized trial of diet in men on active surveillance for prostate cancer
J Kellogg Parsons, John P Pierce, James Mohler, et al.
Contemporary Clinical Trials Communications
|
July 17, 2018
PALINA: A phase II safety study of palbociclib in combination with letrozole or fulvestrant in African American women with hormone receptor positive HER2 negative advanced breast cancer
Filipa Lynce, Mervat Saleh, Ayesha Shajahan-Haq, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
February 6, 2017
Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study-CALGB 30607 (Alliance)
Maria Q Baggstrom, Mark A Socinski, Xiaofei F Wang, et al.
Breast Cancer Research and Treatment
|
February 10, 2025
A randomized phase II trial of nab-paclitaxel with or without mifepristone for advanced triple-negative breast cancer
Nan Chen, Margarite Matossian, Poornima Saha, et al.
The Oncologist
|
August 11, 2019
Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial
Daniel J George, Colin Hessel, Susan Halabi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 16, 2017
Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial
Toni K Choueiri, Susan Halabi, Ben L Sanford, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 2, 2018
Corrigendum to 'Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update' [Eur J Cancer 94 (May 2018) 115-125]
Toni K Choueiri, Colin Hessel, Susan Halabi, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 19, 2018
Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update
Toni K Choueiri, Colin Hessel, Susan Halabi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 4, 2016
Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance)
Maura N Dickler, William T Barry, Constance T Cirrincione, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 23, 2020
Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer
Aranzazu Fernandez-Martinez, Ian E Krop, David W Hillman, et al.
Page
of 4